1 week Ago By ABMN Staff
Barclays PLC raised its stake in Terns Pharmaceuticals, Inc. ( NASDAQ:TERN – Free Report ) by 444.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The fund owned 704,371 shares of the company’s stock after acquiring an additional 575,069 shares during the quarter. Barclays PLC’s holdings in Terns Pharmaceuticals were worth $3,903,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds have also recently modified their holdings of TERN.
Candriam S.C.A.
purchased a new stake in Terns Pharmaceuticals in the fourth quarter worth $11,933,000. Norges Bank purchased a new stake in Terns Pharmaceuticals in the 4th quarter worth about $4,706,000. Vanguard Group Inc.
increased its holdings in Terns Pharmaceuticals by 15.3% in the 4th quarter. Vanguard Group Inc.
now owns 3,869,582 shares of the company’s stock worth $21,437,000 after acquiring an additional 512,768 shares during the last quarter. Geode Capital Management LLC raised its stake in Terns Pharmaceuticals by 25.6% in the 4th quarter.
Geode Capital Management LLC now owns 1,516,478 shares of the company’s stock valued at $8,403,000 after acquiring an additional 308,999 shares during the period. Finally, LPL Financial LLC lifted its holdings in Terns Pharmaceuticals by 397.2% during the fourth quarter.
LPL Financial LLC now owns 252,325 shares of the company’s stock valued at $1,398,000 after purchasing an additional 201,575 shares during the last quarter. 98.26% of the stock is owned by institutional investors.
Analysts Set New Price Targets Several analysts have recently issued reports on TERN shares. William Blair reissued a “market perform” rating on shares of Terns Pharmaceuticals in a research report on Friday, March 21st. JMP Securities reaffirmed a “market outperform” rating and issued a $20.
00 price target on shares of Terns Pharmaceuticals in a report on Monday, April 21st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.
38. Terns Pharmaceuticals Trading Down 4.3 % Terns Pharmaceuticals stock opened at $2.
92 on Monday. Terns Pharmaceuticals, Inc. has a 1-year low of $1.
87 and a 1-year high of $11.40. The firm has a market capitalization of $254.
91 million, a PE ratio of -2.47 and a beta of -0.13.
The firm’s 50 day simple moving average is $3.02 and its 200 day simple moving average is $4.87.
Terns Pharmaceuticals ( NASDAQ:TERN – Get Free Report ) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.
30) by $0.06. Research analysts forecast that Terns Pharmaceuticals, Inc.
will post -1.19 earnings per share for the current year. Terns Pharmaceuticals Company Profile ( Free Report ) Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity.
The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. Recommended Stories Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc.
( NASDAQ:TERN – Free Report ). Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
